Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ProMIS Neurosciences Inc.

< Previous 1 2 Next >
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences, Inc. Announces Leadership Transition
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Announces Completion of Continuance
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Tickers PMN TSX:PMN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS